Quirk Erin 4
4 · Terns Pharmaceuticals, Inc. · Filed Jan 25, 2024
Insider Transaction Report
Form 4
Quirk Erin
President, Head of R&D
Transactions
- Award
Common Stock
[F1]2024-01-23+75,000→ 75,000 total - Award
Stock Option (Right to Buy)
[F2]2024-01-23+150,000→ 150,000 totalExercise: $5.46Exp: 2034-01-22→ Common Stock (150,000 underlying)
Footnotes (2)
- [F1]Each share is represented by a Restricted Stock Unit ("RSU"). 25% of the RSUs vest on the first anniversary measured from January 1, 2024 (the "Vesting Commencement Date"), and 1/16th of the total number of shares vest quarterly thereafter, such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.
- [F2]25% of the shares subject to the option vest on the first anniversary measured from January 1, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.
Signature
/s/ Bryan Yoon, as Attorney-in-Fact for Erin Quirk|2024-01-25